[Influence of Obesity on Urological Malignancies]

Overview

Journal Urologe A

Specialty Urology

Date 2013 Aug 27

PMID 23975219

Citations 1

Authors

H Eggers

M A Kuczyk

A J Schrader

S Steffens

Affiliations

Soon will be listed here.

Abstract

Background: Overweight presents a growing problem in our society; therefore, there is an increasing interest to understand the influence of obesity on urological forms of cancer.

Aim: In prostate cancer the development of a more aggressive phenotype seems to correlate with obesity. In renal cell cancer (RCC) obesity is both, a risk factor for occurrence -and is also associated with an improved tumour-specific survival in patients with organ-confined disease following kidney surgery as well as overall survival of patients with advanced disease receiving VEGF(R)-targeted treatment. In contrast, even though an association between body mass index (BMI) and bladder cancer has been described the role of obesity in bladder cancer remains largely unclear as published data are contradictory.

Results: An update on currently available data focusing on the relationship between obesity and genitourinary malignancies is given in this review; however, basic research which is necessary to define the biological and metabolic effects associated with obesity and which might affect the development and progression of urological cancers, is indicated.

Citing Articles

The Sirenic Links between Diabetes, Obesity, and Bladder Cancer.

Gill E, Sandhu G, Ward D, Perks C, Bryan R Int J Mol Sci. 2021; 22(20).

PMID: 34681810 PMC: 8539374. DOI: 10.3390/ijms222011150.

References

Freedland S, Platz E, Presti Jr J, Aronson W, Amling C, Kane C . Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection. J Urol. 2006; 175(2):500-4. DOI: 10.1016/S0022-5347(05)00162-X. View

Fesinmeyer M, Gulati R, Zeliadt S, Weiss N, Kristal A, Etzioni R . Effect of population trends in body mass index on prostate cancer incidence and mortality in the United States. Cancer Epidemiol Biomarkers Prev. 2009; 18(3):808-15. PMC: 2750884. DOI: 10.1158/1055-9965.EPI-08-0784. View

Setiawan V, Stram D, Nomura A, Kolonel L, Henderson B . Risk factors for renal cell cancer: the multiethnic cohort. Am J Epidemiol. 2007; 166(8):932-40. DOI: 10.1093/aje/kwm170. View

Stewart S, Freedland S . Influence of obesity on the incidence and treatment of genitourinary malignancies. Urol Oncol. 2010; 29(5):476-86. DOI: 10.1016/j.urolonc.2009.12.011. View

Gong Z, Neuhouser M, Goodman P, Albanes D, Chi C, Hsing A . Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev. 2006; 15(10):1977-83. DOI: 10.1158/1055-9965.EPI-06-0477. View

Calle E, Rodriguez C, Walker-Thurmond K, Thun M . Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003; 348(17):1625-38. DOI: 10.1056/NEJMoa021423. View

Rodriguez C, Freedland S, Deka A, Jacobs E, McCullough M, Patel A . Body mass index, weight change, and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev. 2006; 16(1):63-9. DOI: 10.1158/1055-9965.EPI-06-0754. View

Loeb S, Yu X, Nadler R, Roehl K, Han M, Hawkins S . Does body mass index affect preoperative prostate specific antigen velocity or pathological outcomes after radical prostatectomy?. J Urol. 2006; 177(1):102-6. DOI: 10.1016/j.juro.2006.08.097. View

Bergstrom A, Hsieh C, Lindblad P, Lu C, Cook N, Wolk A . Obesity and renal cell cancer--a quantitative review. Br J Cancer. 2001; 85(7):984-90. PMC: 2375100. DOI: 10.1054/bjoc.2001.2040. View

10.

Chow W, McLaughlin J, Mandel J, Wacholder S, Niwa S, Fraumeni Jr J . Obesity and risk of renal cell cancer. Cancer Epidemiol Biomarkers Prev. 1996; 5(1):17-21. View

11.

De Marzo A, Platz E, Sutcliffe S, Xu J, Gronberg H, Drake C . Inflammation in prostate carcinogenesis. Nat Rev Cancer. 2007; 7(4):256-69. PMC: 3552388. DOI: 10.1038/nrc2090. View

12.

Lowrance W, Thompson R, Yee D, Kaag M, Donat S, Russo P . Obesity is associated with a higher risk of clear-cell renal cell carcinoma than with other histologies. BJU Int. 2009; 105(1):16-20. PMC: 2818114. DOI: 10.1111/j.1464-410X.2009.08706.x. View

13.

Fowke J, Motley S, Wills M, Cookson M, Concepcion R, Eckstein C . Prostate volume modifies the association between obesity and prostate cancer or high-grade prostatic intraepithelial neoplasia. Cancer Causes Control. 2007; 18(4):375-84. DOI: 10.1007/s10552-007-0119-x. View

14.

Banez L, Hamilton R, Partin A, Vollmer R, Sun L, Rodriguez C . Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA. 2007; 298(19):2275-80. DOI: 10.1001/jama.298.19.2275. View

15.

Holick C, Giovannucci E, Stampfer M, Michaud D . Prospective study of body mass index, height, physical activity and incidence of bladder cancer in US men and women. Int J Cancer. 2006; 120(1):140-6. DOI: 10.1002/ijc.22142. View

16.

MacInnis R, English D . Body size and composition and prostate cancer risk: systematic review and meta-regression analysis. Cancer Causes Control. 2006; 17(8):989-1003. DOI: 10.1007/s10552-006-0049-z. View

17.

Dahle S, Chokkalingam A, Gao Y, Deng J, Stanczyk F, Hsing A . Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. J Urol. 2002; 168(2):599-604. View

18.

Spyridopoulos T, Petridou E, Dessypris N, Terzidis A, Skalkidou A, Deliveliotis C . Inverse association of leptin levels with renal cell carcinoma: results from a case-control study. Hormones (Athens). 2009; 8(1):39-46. DOI: 10.14310/horm.2002.1220. View

19.

Yu M, Asal N, Geyer J . Later recurrence and longer survival among obese patients with renal cell carcinoma. Cancer. 1991; 68(7):1648-55. DOI: 10.1002/1097-0142(19911001)68:7<1648::aid-cncr2820680731>3.0.co;2-5. View

20.

Schnoeller T, Jentzmik F, Rinnab L, Cronauer M, Damjanoski I, Zengerling F . Circulating free testosterone is an independent predictor of advanced disease in patients with clinically localized prostate cancer. World J Urol. 2012; 31(2):253-9. DOI: 10.1007/s00345-012-0902-5. View